Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells

Oral Oncology

Volumn 44, Issue 7, 2008, Pages 639-645

  Pan, Caobing ^a   Yan, Min ^b   Yao, Jine ^b   Xu, Jie ^b   Long, Zijie ^b   Huang, Hongzhang ^a   Liu, Quentin ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Apoptosis; Aur A; Biomarker; Molecular target

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AURORA A KINASE; AURORA KINASE INHIBITOR; CASPASE 3; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; HISTONE H3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DNA DEGRADATION; DRUG EFFECT; HUMAN; HUMAN CELL; MITOSIS SPINDLE; MOUTH CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANEUPLOIDY; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CATTLE; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MICE; MITOTIC SPINDLE APPARATUS; MOUTH NEOPLASMS; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 45249106814     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.08.010     Document Type: Article

References (48)

1. Chin D., Boyle G.M., Porceddu S., Theile D.R., Parsons P.G., and Coman W.B. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 6 (2006) 1111-1118
2. Mao L., Hong W.K., and Papadimitrakopoulou V.A. Focus on head and neck cancer. Cancer Cell 5 (2004) 311-316
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
4. Ongkeko W.M., Altuna X., Weisman R.A., and Wang-Rodriguez J. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124 (2005) 71-76
5. Freier K., Bosch F.X., Flechtenmacher C., Devens F., Benner A., Lichter P., et al. Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. Anticancer Res 23 (2003) 3971-3977
6. Almadori G., Cadoni G., Cattani P., Galli J., Bussu F., Ferrandina G., et al. Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma. Clin Cancer Res 7 (2001) 3988-3993
7. Rubin Grandis J., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
8. Maurizi M., Almadori G., Ferrandina G., Distefano M., Romanini M.E., Cadoni G., et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Brit J Cancer 74 (1996) 1253-1257
9. Sathyan K.M., Nalinakumari K.R., Abraham T., and Kannan S. Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility. Oral Oncol 42 (2006) 607-613
10. Auerkari E.I. Methylation of tumor suppressor genes p16(INK4a), p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol 42 (2006) 5-13
11. Wang L., Liu T., Nishioka M., Aguirre R.L., Win S.S., and Okada N. Activation of ERK1/2 and cyclin D1 expression in oral tongue squamous cell carcinomas: relationship between clinicopathological appearances and cell proliferation. Oral Oncol 42 (2006) 625-631
12. He Y., Zeng Q., Drenning S.D., Melhem M.F., Tweardy D.J., Huang L., et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 90 (1998) 1080-1087
13. Caponigro F., Milano A., Basile M., Ionna F., and Iaffaioli R.V. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents. Curr Opin Oncol 18 (2006) 247-252
14. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102 (2005) 11011-11016
15. Harari P.M., and Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin Radiat Oncol 16 (2006) 38-44
16. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 354 (2006) 567-578
17. Meraldi P., Honda R., and Nigg E.A. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 14 (2004) 29-36
18. Ducat D., and Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 301 (2004) 60-67
19. Andrews P.D., Knatko E., Moore W.J., and Swedlow J.R. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 15 (2003) 672-683
20. Marumoto T., Zhang D., and Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer 5 (2005) 42-50
21. Hsu J.Y., Sun Z.W., Li X., Reuben M., Tatchell K., Bishop D.K., et al. Mitotic phosphorylation of histone H3 is governed by Ipl1/aurora kinase and Glc7/PP1 phosphatase in budding yeast and nematodes. Cell 102 (2000) 279-291
22. Tang C.J., Lin C.Y., and Tang T.K. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 290 (2006) 398-410
23. Dieterich K., Soto Rifo R., Faure A.K., Hennebicq S., Ben Amar B., Zahi M., et al. Homozygous mutation of AURKC yields large-headed polyploid spermatozoa and causes male infertility. Nat Genet 39 (2007) 661-665
24. Zou L.J., Li G.Q., Gong L.L., Wang Y., Jin W., Zhao J.Y., et al. Expression of aurora-A kinase in human lung cancer cell lines PG, A549, and NCI-H460. Ai Zheng 24 (2005) 792-795
25. Li X., Sakashita G., Matsuzaki H., Sugimoto K., Kimura K., Hanaoka F., et al. Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J Biol Chem 279 (2004) 47201-47211
26. Sampath S.C., Ohi R., Leismann O., Salic A., Pozniakovski A., and Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell 118 (2004) 187-202
27. Crane R., Gadea B., Littlepage L., Wu H., and Ruderman J.V. Aurora A, meiosis and mitosis. Biol Cell 96 (2004) 215-229
28. Andrews P.D. Aurora kinases: shining lights on the therapeutic horizon?. Oncogene 24 (2005) 5005-5015
29. Zhou H., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20 (1998) 189-193
30. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J 17 (1998) 3052-3065
31. Sen S., Zhou H., and White R.A. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 14 (1997) 2195-2200
32. Yamamoto Y., Matsuyama H., Kawauchi S., Furuya T., Liu X.P., Ikemoto K., et al. Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res 12 (2006) 2752-2758
33. Li D., Zhu J., Firozi P.F., Abbruzzese J.L., Evans D.B., Cleary K., et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9 (2003) 991-997
34. Lee E.C., Frolov A., Li R., Ayala G., and Greenberg N.M. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 66 (2006) 4996-5002
35. Tatsuka M., Sato S., Kitajima S., Suto S., Kawai H., Miyauchi M., et al. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 24 (2005) 1122-1127
36. Qi G., Ogawa I., Kudo Y., Miyauchi M., Siriwardena B.S., Shimamoto F., et al. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch 450 (2007) 297-302
37. Keen N., and Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4 (2004) 927-936
38. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10 (2004) 262-267
39. Shi Y., Reiman T., Li W., Maxwell C.A., Sen S., Pilarski L., et al. Targeting aurora kinases as therapy in multiple myeloma. Blood 109 (2007) 3915-3921
40. Liu Q., and Ruderman J.V. Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci USA 103 (2006) 5811-5816
41. Ikezoe T., Yang J., Nishioka C., Tasaka T., Taniguchi A., Kuwayama Y., et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 6 (2007) 1851-1857
42. Hauf S., Cole R.W., LaTerra S., Zimmer C., Schnapp G., Walter R., et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161 (2003) 281-294
43. Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., and Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109 (2007) 500-502
44. Soncini C., Carpinelli P., Gianellini L., Fancelli D., Vianello P., Rusconi L., et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 12 (2006) 4080-4089
45. Wilkinson R.W., Odedra R., Heaton S.P., Wedge S.R., Keen N.J., Crafter C., et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13 (2007) 3682-3688
46. Tong T., Zhong Y., Kong J., Dong L., Song Y., Fu M., et al. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 10 (2004) 7304-7310
47. Sen S., Zhou H., Zhang R.D., Yoon D.S., Vakar-Lopez F., Ito S., et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94 (2002) 1320-1329
48. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609-619